Who is sponsoring NCT07519187?

NCT07519187 is sponsored by The General Hospital of Western Theater Command.

What drugs are being tested in NCT07519187?

Interventions in NCT07519187: CAR 70-BCMA CAR-T, Fludarabine and Cyclophosphamide.

What condition does NCT07519187 study?

NCT07519187 studies Relapsed or Refractory Plasma Cell Neoplasms.

Is NCT07519187 still recruiting?

NCT07519187 is currently not yet recruiting. Last updated 9 April 2026.

Last reviewed 2026-04-09 · How we verify

NCT07519187

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

Not yet recruiting EARLY_PHASE1 Last updated 9 April 2026

What this trial tests

EARLY_PHASE1 trial testing CAR 70-BCMA CAR-T in Relapsed or Refractory Plasma Cell Neoplasms in 20 participants. Not yet recruiting.

Timeline

3 April 2026

Primary endpoint
1 April 2027

1 April 2028

Quick facts

Lead sponsor	The General Hospital of Western Theater Command
Phase	EARLY_PHASE1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	3 April 2026
Primary completion	1 April 2027
Estimated completion	1 April 2028
Sites	1 location across China

Drugs / interventions tested

CAR 70-BCMA CAR-T
Fludarabine and Cyclophosphamide — full drug profile →

Conditions studied

Relapsed or Refractory Plasma Cell Neoplasms — all drugs for Relapsed or Refractory Plasma Cell Neoplasms →

Sponsor

The General Hospital of Western Theater Command

Who can join

Adults 18 to 75, any sex, with Relapsed or Refractory Plasma Cell Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm study to evaluate the safety and efficacy of CAR70-BCMA dual-target CAR-T cell therapy for relapsed and refractory plasma cell neoplasms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other The General Hospital of Western Theater Command trials

Trials by the same sponsor.

NCT07205250 — Aspirin for Prevention of Stroke After Endovascular Aortic Arch Repair: a Multicenter, Double-Blind, Randomized Controll · EARLY_PHASE1 · not yet recruiting
NCT07483385 — Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation · NA · recruiting
NCT07256353 — Allogeneic UCB-derived CAR-T for B-ALL · EARLY_PHASE1 · not yet recruiting
NCT07277504 — Autologous Bedside CD19 CAR T-cell Therapy for B-ALL · EARLY_PHASE1 · not yet recruiting
NCT06684639 — A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07519187 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The General Hospital of Western Theater Command
Last refreshed: 9 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07519187.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing